<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591188</url>
  </required_header>
  <id_info>
    <org_study_id>CRT-003</org_study_id>
    <secondary_id>CRT-003</secondary_id>
    <nct_id>NCT00591188</nct_id>
  </id_info>
  <brief_title>Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens</brief_title>
  <official_title>Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kidney Cancer Research Bureau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kidney Cancer Research Bureau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine preliminary efficacy of capecitabine and&#xD;
      interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate progression-free survival with capecitabine and interferon treatment in metastatic renal cell carcinoma (MRCC) patients (pts) with IL-2 failure in first-line</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of the capecitabine and interferon combination</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate response rate and overall survival with the capecitabine and interferon combination in MRCC pts with progression on IL-2 based regimens</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive capecitabine and interferon-alpha.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine, interferon-alpha</intervention_name>
    <description>Patients who meet inclusion/exclusion criteria will receive combination of study drugs.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed renal carcinoma&#xD;
&#xD;
          -  CT-confirmed metastatic sites&#xD;
&#xD;
          -  Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion&#xD;
             measured as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with spiral CT scan&#xD;
&#xD;
          -  Disease progression after IL-2&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  ECOG performance status 1-3&#xD;
&#xD;
          -  Life expectancy ≥ 2 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 7.5 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL (2.0 mg/dL in post-nephrectomy patients)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST ≤ 3.0 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times normal (10 times ULN in presence of bone metastases)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No history of autoimmune&#xD;
&#xD;
          -  No history of serious cardiac arrhythmia, congestive heart failure, angina pectoris,&#xD;
             or other severe cardiovascular disease (i.e., New York Heart Association class III or&#xD;
             IV)&#xD;
&#xD;
          -  No CNS metastases by neurologic exam and/or MRI&#xD;
&#xD;
          -  No history of seizure disorders&#xD;
&#xD;
          -  No local and/or systemic infections requiring antibiotics within 28 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  No other malignancy&#xD;
&#xD;
          -  Written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya V. Tsimafeyeu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kidney Cancer Research Bureau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lev V. Demidov, MD, DSc.</last_name>
    <role>Study Director</role>
    <affiliation>N.N. Blokhin Russian Cancer Research Bureau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>N.N. Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>April 30, 2009</last_update_submitted>
  <last_update_submitted_qc>April 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ilya Tsimafeyeu, MD</name_title>
    <organization>Kidney Cancer Research Bureau</organization>
  </responsible_party>
  <keyword>kidney cancer, capecitabine, interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

